SCHEDULE 13G/A: RA Capital Management Discloses 9.9% Stake in Monopar Therapeutics

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G/A, disclosing a 9.9% beneficial ownership stake in Monopar Therapeutics Inc. as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an amended Schedule 13G/A regarding their beneficial ownership in Monopar Therapeutics Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 620,116 shares of Monopar Therapeutics Inc. Common Stock.
• This represents a 9.9% beneficial ownership stake in the company, rounded down from 9.99% due to EDGAR filing system limitations.
• The ownership calculation is based on 6,098,467 outstanding shares as of December 23, 2024, plus 108,909 shares issuable from exercisable pre-funded warrants.
• RA Capital Healthcare Fund, L.P. directly holds 511,207 shares of Common Stock and pre-funded warrants exercisable for up to 882,761 shares.
• The pre-funded warrants include a "Beneficial Ownership Blocker" provision, preventing exercise if it would result in ownership exceeding 9.99% of outstanding Common Stock.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
• RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, while Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or outlook. The 9.9% stake by a notable healthcare fund is a neutral, albeit significant, piece of information.

Positives

• A significant institutional investor, RA Capital Management, maintains a substantial 9.9% stake in Monopar Therapeutics, indicating continued investment interest.
• The presence of a "Beneficial Ownership Blocker" in the pre-funded warrants demonstrates a mechanism to prevent immediate dilution beyond a certain threshold, potentially stabilizing the ownership percentage.

Negatives

• The filing itself does not contain negative financial or operational information about Monopar Therapeutics Inc., as it is solely an ownership disclosure.

Risks

• The "Beneficial Ownership Blocker" limits the immediate exercise of pre-funded warrants to prevent ownership exceeding 9.99%, which could impact the timing or extent of future capital deployment by RA Capital if they wished to increase their stake beyond this threshold without triggering additional reporting requirements or control implications.
• The Reporting Persons disclaim beneficial ownership for purposes other than Section 13(d) obligations, indicating their intent is not to control the issuer, which might limit their active involvement in corporate governance beyond their investment.

Future Outlook

The document is a beneficial ownership filing and does not contain forward-looking statements or guidance regarding Monopar Therapeutics Inc.'s future operations or financial performance.

Management Comments

• The filing includes a certification by the Reporting Persons that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology or pharmaceutical sector, specifically in Monopar Therapeutics Inc., a company likely involved in drug development given its name. Such significant stakes by specialized healthcare funds are common in the biotech industry, where early-stage companies often rely on institutional capital.

Comparison to Industry Standards

• This is a standard Schedule 13G/A filing, which is a regulatory disclosure of beneficial ownership.
• The 9.9% stake is a significant minority position, typical for institutional investors like RA Capital Management in smaller-cap biotechnology companies.
• The inclusion of a 'Beneficial Ownership Blocker' is a common mechanism used by investors to avoid triggering the 10% beneficial ownership threshold, which would require filing a Schedule 13D and potentially imply an intent to influence or control the company. This practice is standard for passive investors seeking to maintain flexibility while holding a substantial stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.
• Management: Awareness of a large, passive institutional holder, which may influence strategic decisions or communication.

Next Steps

• The document does not specify future actions or milestones for Monopar Therapeutics Inc. or the Reporting Persons beyond the ongoing reporting requirements for beneficial ownership.

Key Dates

Keywords

Monopar Therapeutics Inc., RA Capital Management, Schedule 13G/A, Beneficial Ownership, Institutional Investor, Healthcare Fund, Common Stock, Pre-funded Warrants, SEC Filing, Investment